IL166756A0 - A pharmaceutical composition containing a compoundthat reduces activity of MK2 and methods for iden tifying such compounds - Google Patents

A pharmaceutical composition containing a compoundthat reduces activity of MK2 and methods for iden tifying such compounds

Info

Publication number
IL166756A0
IL166756A0 IL16675605A IL16675605A IL166756A0 IL 166756 A0 IL166756 A0 IL 166756A0 IL 16675605 A IL16675605 A IL 16675605A IL 16675605 A IL16675605 A IL 16675605A IL 166756 A0 IL166756 A0 IL 166756A0
Authority
IL
Israel
Prior art keywords
compoundthat
compounds
methods
pharmaceutical composition
composition containing
Prior art date
Application number
IL16675605A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL166756A0 publication Critical patent/IL166756A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16675605A 2002-08-23 2005-02-08 A pharmaceutical composition containing a compoundthat reduces activity of MK2 and methods for iden tifying such compounds IL166756A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40558602P 2002-08-23 2002-08-23
PCT/US2003/026337 WO2004017909A2 (en) 2002-08-23 2003-08-21 Methods of reducing ischemic injury

Publications (1)

Publication Number Publication Date
IL166756A0 true IL166756A0 (en) 2006-01-15

Family

ID=31946902

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16675605A IL166756A0 (en) 2002-08-23 2005-02-08 A pharmaceutical composition containing a compoundthat reduces activity of MK2 and methods for iden tifying such compounds

Country Status (7)

Country Link
US (1) US20040110710A1 (de)
EP (1) EP1546181A2 (de)
JP (1) JP2006502142A (de)
AU (1) AU2003259991A1 (de)
IL (1) IL166756A0 (de)
MX (1) MXPA05001918A (de)
WO (1) WO2004017909A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053610A2 (en) * 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP6145089B2 (ja) 2011-06-07 2017-06-07 メソブラスト インターナショナル エスエイアールエル ストロマ細胞由来因子−１のプロテアーゼ耐性変異体を用いた、組織損傷を修復するための方法

Also Published As

Publication number Publication date
WO2004017909A2 (en) 2004-03-04
US20040110710A1 (en) 2004-06-10
EP1546181A2 (de) 2005-06-29
MXPA05001918A (es) 2005-04-28
WO2004017909A3 (en) 2004-08-19
JP2006502142A (ja) 2006-01-19
AU2003259991A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
IL190218A0 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
GB2394894B (en) New use for pharmaceutical composition
PL360967A1 (en) Pharmaceutical compound containing donepezyl hydrochloride
IL173639A0 (en) Ppar-activating compound and pharmaceutical composition containing same
IL162796A0 (en) Medicinal compositions containing ghrelin
IL164987A0 (en) Proline derivatives and pharmaceutical compositions containing
IL158493A0 (en) Pharmaceutical compositions containing venlafaxine
IL209444A0 (en) O-desmethyl-venlafaxine succinate salts and pharmaceutical compositions containing them
IL165511A0 (en) A process for preparing sulfoxide compounds compounds prepared thereby and pharmaceutical compositions containing the same
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
AU2003291103A8 (en) Pharmaceutical composition
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
IL200849A0 (en) Pharmaceutical composition comprising bisphosphonate for oral application and a process for its prepatrtion
AU2003250372A8 (en) Pharmaceutical composition
AU2003210975A8 (en) Compounds for inhibiting insulin secretion and methods related thereto
EP1589950A4 (de) Verfahren zur herstellung pharmazeutischer darreichungsformen mit aktiven kompressionsbestandteilen
ZA200500203B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
GB0207092D0 (en) Stable pharmaceutical composition containing factor VIII
AU2003231920A8 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
EP1484061A4 (de) Arzneimittel mit verbindungen vom riboflavin-typ
HUP0600855A2 (en) Androgen pharmaceutical composition for treating depression
IL153098A0 (en) Pharmaceutical compositions containing modafinil
ZA200500431B (en) Medicinal composition for treating arteriosclerosis
PL374965A1 (en) Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
AU2003274655A8 (en) Pharmaceutical compositions containing venlafaxine